Natco’s marketing partner Alvogen receives USFDA approval for chest pain tablets
Mumbai, : Pharma Major Natco Pharma Limited said that its marketing partner Alvogen has received the final approval of Abbreviated New Drug Application (ANDA) from the USFDA for chest pain tablets.
The company has received the final approval of Abbreviated New Drug Application (ANDA) from the United States Food and Drug Administration (FDA) for Nitroglycerin Sublingual Tablets USP, 0.3 mg, 0.4 mg, and 0.6 mg, Natco Pharma said in a BSE filing.
Pfizer Pharmaceuticals Ltd markets this drug under its brand Nitrostat Sublingual Tablets in the same strengths mentioned above.
As per IQVIA data, Nitroglycerin Sublingual Tablets had total annual sales of around USD 77.3 million in the US market, for the year ending 2018.
(UNI)